Ichor Medical Systems said today that its TriGrid electroporation drug-delivery system was tapped for a Phase Ib/II clinical trial to administer an investigational therapeutic HPV DNA vaccine, GX-188E, developed by Genexine Inc.
The trial is designed to test the efficacy of a DNA vaccine combined with an anti-PD-1 therapy in patients with HPV-induced advanced non-resectable cervical cancer.
Get the full story at our sister site, Drug Delivery Business News.
The post Ichor touts use of electroporation drug-delivery system in cervical cancer trial appeared first on MassDevice.
from MassDevice https://ift.tt/2LfuUjL
Cap comentari:
Publica un comentari a l'entrada